APR March 2024 - 46

» PARTNER PERSPECTIVE
Lipid nanoparticles as vehicles for ocular delivery - Saturated lipid
nanoparticles, nanostructured lipid carriers, liposomes, cubosomes,
micro- and nanoemulsions; nanosuspensions, dendrimers, micelles
among others a range of carriers for ocular or ophthalmic delivery.
Table 1 cites many examples of drugs investigated by ocular delivery.5-18
Ocular Approved Drugs
Several drugs have been approved employing the nanoparticle
technologies for the treatment of diseases affecting the anterior
segment of the eye as shown in Table 2.3
Conclusion and Future Perspectives
Ocular drug delivery is challenging due to many anatomical
barriers. Nanoparticle technologies in ocular delivery, however, have
demonstrated wide utilities across all molecules, small and large. We
believe that nanoparticle technology will gain steam in ocular delivery
for launch of new molecules to market with more innovative polymeric
and lipid assemblies.
Ascendia's platform technologies, NanoSol® (nanosuspension),
EmulSol® (microemulsion) and LipidSol® (lipid nanoparticles) are
primed to address the challenges with poorly soluble drugs. For
instance, Ascendia® using its EmulSol technology, by top down or
bottom-up approach has enabled the manufacturing of nanoparticle
formulations with controlled particle sizes (< 50 nm) comprised of
0.05% Cyclosporine A, soybean oil, lecithin, and polysorbate 80.19
With its cGMP manufacturing capabilities of sterile drug products,
Ascendia is poised to tackle the challenges to address the unmet
medical needs by designing better and smarter polymeric and lipid
nanoparticle formulations in the future.
References
1.
2.
8.
5.
E. Terreni, E. Zucchetti, S. Tampucci, S. Burgalassi, D. Monti, P. Chetoni, Combination of
Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System
(ODDS) for Cyclosporine-A, Pharmaceutics, 2021, 13, 192.
6.
Y. Yu, D. Chen, Y. Li, W. Yang, J. Tu, and Y. Shen, Improving the topical ocular pharmacokinetics
of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies,
Drug Deliv. 25 (2018) 888-899.
7.
S. Akhter, M. Anwar, M. A. Siddiqui, I. Ahmad, J. Ahmad, and M. Z. Ahmad, A. Bhatnagar,
and F. J. Ahmad, Improving the topical ocular pharmacokinetics of an immunosuppressant
agent with mucoadhesive nanoemulsions: Formulation development, in-vitro and in-vivo
studies, Colloids Surf. B: Biointerfaces, 2016, 148,19-29.
A. L. Onugwu, A. A. Attama, P. O. Nnamani, S. O. Onugwu, E. B. Onuigbo, and V. V.
Khutoryanskiy, Development and optimization of solid lipid nanoparticles coated with
chitosan and poly(2-ethyl-2-oxazoline) for ocular drug delivery of ciprofloxacin, J. Drug
Deliv. Sci. Technol., 2022, 74, 103527.
9. W.S. Alharbi and K.M. Hosny, Development and optimization of ocular in situ gels loaded
with ciprofloxacin cubic liquid crystalline nanoparticles, J. Drug Deliv. Sci. Technol., 2020,
57, 101710.
10.
I.A. Khalil, I.H. Ali, I.M. El-Sherbiny, Noninvasive biodegradable nanoparticles-in nanofibers
single-dose ocular insert: in vitro, ex vivo and in vivo evaluation, Nanomedicine, 2019, 14,
33-55.
11. W. Zeng, Q. Li, T. Wan, C. Liu, W. Pan, Z. Wu, G. Zhang, J. Pan, M. Qin, Y. Lin, C. Wu, Y. Xu,
Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion,
precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability,
Colloids Surf. B: Biointerfaces, 2016, 141, 28-35.
12. D. Modi, M.H. Mohammad, V. Warsi, M. Garg, P. Bhatia, and G.K. K. Jain, Formulation
development, optimization, and in vitro assessment of thermoresponsive ophthalmic
pluronic F127-chitosan in situ tacrolimus gel, J. Biomater. Sci. Polym. Ed., 2021, 32,
1678-1702.
13.
B. Xu and T. Liu, Travoprost loaded microemulsion soaked contact lenses: Improved drug
uptake, release kinetics and physical properties, J. Drug Deliv. Sci. Technol., 2020, 57,
101792.
14. M. Gomez-Ballesteros, J. J. Lopez-Cano, I. Bravo-Osuna, R. Herrero-Vanrell, and I. T. MolinaMartinez,
Osmoprotectants in hybrid liposome/HPMC systems as potential glaucoma
treatment, Polymers 2019, 11, 929.
15.
J. Huang and S. Ali, Lipid Nanoparticles: Tackling solubility challenges with lipid-based
technologies for oral and injectable formulations, Drug Dev. Delivery, 2022 November.
I. Elsayed and S. Syed, Tailored nanostructured platforms for boosting transcorneal
permeation: Box-Behnken statistical optimization, comprehensive in vitro, ex vivo and in
vivo characterization, Nanomedicine 2017, 12, 7947-7962.
17.
3.
A. L. Onugwa, C. S. Nwagwu, O. S. Onugwu, A. C. Echezona, C. P. Agbo, S. A. Ihim, P. Emeh,
P. O. Nnamani, A. A. Attama, and V. V. Khutoryanskiy, Nanotechnology based drug delivery
systems for the treatment of anterior segment eyes diseases, J. Control. Release, 2023, 354,
465-468.
4.
P. L. Destruel, N. Zeng, M. Maury, N. Mignet and V. Boudy, In vitro and in vivo evaluation
of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and
beyond, Drug Discovery Today, 2017, 22, 638-651.
46 |
| March 2024
N. Seedat, R.S. Kalhapure, C. Mocktar, S. Vepuri, M. Jadhav, M. Soliman, T. Govender, Coencapsulation
of multi-lipids and polymers enhances the performance of vancomycin in
lipid-polymer hybrid nanoparticles: In vitro and in silico studies, Mater. Sci. Eng., 2016,
C 61, 616-630.
16.
S. Kumari, M. Dandamudi, S. Rani, E. Behaeghel, G. Behl, D. Kent, N.J. O'Reilly, O.
O'Donovan, P. McLoughlin, and L. Fitzhenry, Dexamethasone-Loaded Nanostructured Lipid
Carriers for the Treatment of Dry Eye Disease, Pharmaceutics, 2021, 13, 905.
G. Tan, J. Li, Y. Song, Y. Yu, D. Liu, and W. Pan, Phenylboronic acid-tethered chondroitin
sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye
syndrome, Acta Biomater., 2019, 99, 350-362.
18.
T. Fu, J. Yi, S. Lv, and B. Zhang, Ocular amphotericin B delivery by chitosan-modified
nanostructured lipid carriers for fungal keratitis-targeted therapy, J. Liposome Res., 2017,
27, 228-233.
19.
J. Huang, Compositions for nano-emulsion delivery systems, US Patent 10,251,837 (2019).

APR March 2024

Table of Contents for the Digital Edition of APR March 2024

Message from the Editor
Editorial Advisory Board
BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
An Interview with Dan Smithey, PhD President & CEO, Serán
FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
QC Corner - Enhancing Material and Equipment Availability in Production Isolators
BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
DRUG DELIVERY - Your Nails and You
DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
Event Preview - CPHI North America
Event Preview - Excipient World 2024
P.I.N. Points
Advertiser's Index
APR March 2024 - CoverTip01
APR March 2024 - CoverTip02
APR March 2024 - Cover1
APR March 2024 - Cover2
APR March 2024 - 1
APR March 2024 - 2
APR March 2024 - 3
APR March 2024 - 4
APR March 2024 - 5
APR March 2024 - Message from the Editor
APR March 2024 - Editorial Advisory Board
APR March 2024 - BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
APR March 2024 - 9
APR March 2024 - 10
APR March 2024 - 11
APR March 2024 - 12
APR March 2024 - 13
APR March 2024 - MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
APR March 2024 - 15
APR March 2024 - 16
APR March 2024 - 17
APR March 2024 - 18
APR March 2024 - FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
APR March 2024 - 20
APR March 2024 - 21
APR March 2024 - 22
APR March 2024 - 23
APR March 2024 - FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
APR March 2024 - 25
APR March 2024 - 26
APR March 2024 - 27
APR March 2024 - An Interview with Dan Smithey, PhD President & CEO, Serán
APR March 2024 - 29
APR March 2024 - 30
APR March 2024 - FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
APR March 2024 - 32
APR March 2024 - 33
APR March 2024 - QC Corner - Enhancing Material and Equipment Availability in Production Isolators
APR March 2024 - 35
APR March 2024 - BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
APR March 2024 - 37
APR March 2024 - 38
APR March 2024 - 39
APR March 2024 - Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
APR March 2024 - 41
APR March 2024 - MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
APR March 2024 - 43
APR March 2024 - Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
APR March 2024 - 45
APR March 2024 - 46
APR March 2024 - 47
APR March 2024 - DRUG DELIVERY - Your Nails and You
APR March 2024 - 49
APR March 2024 - 50
APR March 2024 - 51
APR March 2024 - DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
APR March 2024 - 53
APR March 2024 - 54
APR March 2024 - 55
APR March 2024 - FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
APR March 2024 - 57
APR March 2024 - Event Preview - CPHI North America
APR March 2024 - 59
APR March 2024 - Event Preview - Excipient World 2024
APR March 2024 - 61
APR March 2024 - P.I.N. Points
APR March 2024 - 63
APR March 2024 - Advertiser's Index
APR March 2024 - Cover3
APR March 2024 - Cover4
https://www.nxtbookmedia.com